“Top pick” focuses on advances in treatment of mCRPC

In a new article on the Practice Update web site, Dr. Howard Scher, an oncologist specializing in treatment of advanced prostate cancer at Memorial Sloan-Kettering Cancer Center in New York, writes about his “top pick” regarding new prostate cancer knowledge from 2013.

Dr Scher discusses the approval of the new α-particle emitting agent known as radium-223 dichloride (Xofigo), our expanding knowledge about the differing subtypes of metastatic, castration-resistant prostate cancer (mCRPC), and our associated expanding understanding of how to select appropriate forms of treatment for men with these differing subtypes of mCRPC.

Editor’s note: Dr. Scher inaccurately refers to radium-223 dichloride by the name “Alpharadin” in his article. Alpharadin was at one point the proposed trade name for radium-223 dichoride; however, the actual trade name finally used here in the USA is Xofigo.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: